CINECA IRIS Institutional Research Information System

PRETE, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.821
AS - Asia 1.628
EU - Europa 1.048
SA - Sud America 304
Continente sconosciuto - Info sul continente non disponibili 114
AF - Africa 102
OC - Oceania 2
Totale 7.019
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.658
SG - Singapore 603
CN - Cina 428
IT - Italia 349
BR - Brasile 249
HK - Hong Kong 225
DE - Germania 151
VN - Vietnam 146
SE - Svezia 114
CA - Canada 94
FR - Francia 76
AT - Austria 65
GB - Regno Unito 57
FI - Finlandia 46
RU - Federazione Russa 39
JP - Giappone 35
BG - Bulgaria 32
CI - Costa d'Avorio 30
IN - India 29
AR - Argentina 24
BD - Bangladesh 23
KR - Corea 22
SN - Senegal 21
PL - Polonia 20
TR - Turchia 20
EE - Estonia 18
MA - Marocco 18
MX - Messico 18
NL - Olanda 18
ZA - Sudafrica 13
ES - Italia 12
IQ - Iraq 10
SA - Arabia Saudita 10
UZ - Uzbekistan 10
ID - Indonesia 9
PK - Pakistan 9
UA - Ucraina 9
EC - Ecuador 8
HN - Honduras 8
GT - Guatemala 7
CL - Cile 6
CZ - Repubblica Ceca 6
GR - Grecia 6
IE - Irlanda 6
LT - Lituania 6
SC - Seychelles 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
CR - Costa Rica 5
IL - Israele 5
JM - Giamaica 5
JO - Giordania 5
MG - Madagascar 5
PH - Filippine 5
AZ - Azerbaigian 4
BB - Barbados 4
KE - Kenya 4
KZ - Kazakistan 4
MY - Malesia 4
PR - Porto Rico 4
TT - Trinidad e Tobago 4
BE - Belgio 3
LV - Lettonia 3
NP - Nepal 3
OM - Oman 3
SV - El Salvador 3
AU - Australia 2
GP - Guadalupe 2
MC - Monaco 2
NI - Nicaragua 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
BH - Bahrain 1
BM - Bermuda 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
KY - Cayman, isole 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
MM - Myanmar 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.904
Salva come PNG Salva come JPEG
Città #
Dallas 565
Ashburn 514
San Jose 363
Singapore 360
Hong Kong 220
Santa Clara 178
Chandler 131
New York 94
Shanghai 92
Munich 88
Los Angeles 87
Council Bluffs 73
Beijing 65
Vienna 61
Pisa 57
Milan 56
Fairfield 49
Boardman 46
Ho Chi Minh City 46
Hefei 34
Sofia 32
Tokyo 32
Princeton 31
Abidjan 30
Hanoi 30
Houston 30
Atlanta 28
Florence 28
Frankfurt am Main 27
Lauterbourg 27
Woodbridge 27
Helsinki 26
Redondo Beach 26
São Paulo 26
Buffalo 25
Rome 25
Cambridge 22
Seoul 22
Dakar 21
London 20
Orem 20
Seattle 20
Wilmington 20
Lawrence 19
North Bergen 17
Turku 17
Brooklyn 16
Washington 16
Medford 15
Montreal 15
Phoenix 15
Chicago 14
Warsaw 14
Columbus 12
Denver 12
Poplar 12
Casablanca 11
Nuremberg 11
Ogden 11
Toronto 11
Johannesburg 10
Cascina 9
Düsseldorf 9
Lucca 9
San Diego 9
Serra 9
Tashkent 9
Vancouver 9
Belo Horizonte 8
Fuzhou 8
Istanbul 8
Memphis 8
Stockholm 8
Abbeville 7
Amsterdam 7
Baltimore 7
Bologna 7
Boston 7
Philadelphia 7
Turin 7
Changchun 6
Da Nang 6
Dulles 6
Jeddah 6
Mexico City 6
Miami 6
Mumbai 6
Paris 6
Quanzhou 6
San Francisco 6
Tampa 6
Amman 5
Antananarivo 5
Baghdad 5
Bremen 5
Charlotte 5
Chiesina Uzzanese 5
Dublin 5
Hải Dương 5
Modena 5
Totale 4.285
Salva come PNG Salva come JPEG
Nome #
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 227
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 206
18F-DOPA-PET/CT role in medullary thyroid cancer patients with biochemical incomplete response 205
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 191
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 184
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 183
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 180
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 178
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 178
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 174
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 167
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 166
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 159
Bilateral testicular metastases of medullary thyroid carcinoma in an adult male with multiple endocrine neoplasia 2A syndrome: case report and review of literature 157
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 152
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 150
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 149
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 148
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 148
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 147
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 146
Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience 145
Erectile dysfunction in patients treated with selpercatinib for RET altered thyroid cancer 144
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 138
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 138
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 138
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 136
Use of non-nutritive-sweetened soft drink and risk of gestational diabetes 134
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 133
Firm mass in thyroid of an elderly patient: Not always cancer 129
Hypothesizing a role of ret hyperactivation on weight control in patients with type 2A multiple endocrine neoplasia (MEN2A) 128
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 128
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 124
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report 122
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 122
Inflammation-based scores in patients with pheochromocytoma 120
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 120
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 117
The challenge of the differential diagnosis between brown tumors and metastases in parathyroid carcinoma: a case report 114
BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review 111
Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination 109
Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib 106
Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules 97
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine 91
Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients 90
Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib 77
State of the Art in 3D Culture Models Applied to Thyroid Cancer 71
Timing and Ideal Patient for an Appropriate Search for Somatic RET Mutation in Medullary Thyroid Cancer 68
Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease 57
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers 46
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment 40
Prevalence and genetics of "de novo" MEN2 syndromes 37
Comparison of pre-operative calcitonin, FNAC, and ultrasound risk stratification systems in patients with medullary thyroid carcinoma 37
Impairment in the hypothalamic-pituitary-gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib 21
null 19
A large series of patients with anaplastic thyroid cancer managed in a tertiary referral center 17
Totale 7.019
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.380
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.380
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022163 0 0 0 0 26 22 13 9 11 12 16 54
2022/2023452 40 49 41 38 51 51 2 41 96 3 32 8
2023/2024343 17 29 54 26 42 66 21 3 5 9 27 44
2024/20251.562 21 58 28 85 160 114 167 86 156 172 199 316
2025/20262.979 202 474 394 305 303 167 374 92 155 245 109 159
2026/20271.328 95 387 258 457 131 0 0 0 0 0 0 0
Totale 7.019